Phase II study of flutamide as second line chemotherapy in patients with advanced pancreatic cancer

摘要: Androgen receptors are present in both pancreatic cancer tissue and cell lines. Flutamide is a potent antiandrogen widely used clinical practice for patients with metastatic prostate cancer. This Phase II trial was undertaken to evaluate the impact of flutamide advanced adenocarcinoma who had developed progressive disease following therapy one 5-FU-based regimen. Fourteen were treated flutamide, 250 mg orally three times per day. Therapy generally well tolerated. No patient achieved objective tumor response. improvement tumor-related symptoms as measured by pain intensity, analgesic requirement, performance status, or nutritional status. Median survival 4.7 months. We conclude that ineffective second line adenocarcinoma.